RANDOMIZED, OPEN-LABEL, PHASE 2 STUDY OF SILTUXIMAB (AN ANTI-IL-6 MAB) AND BORTEZOMIB-MELPHALAN-PREDNISONE VERSUS BORTEZOMIB-MELPHALAN-PREDNISONE IN PATIENTS WITH PREVIOUSLY UNTREATED MULTIPLE MYELOMA

J. San Miguel, J. Blade, O. Samoilova, O. Shpilberg, S. Grosicki, F. Maloisel, C. Min, M. Zarzuela,T. Robak, N. Khuageva, S. Prasad,Y. Goh,J. Laubach, A. Spencer,M. Mateos, A. Palumbo,H. van de Velde, C. Uhlar,X. Qin,H. Xie,R. Orlowski

HAEMATOLOGICA(2013)

引用 0|浏览3
暂无评分
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要